PL3307739T3 - Regulatory nrf2 - Google Patents
Regulatory nrf2Info
- Publication number
- PL3307739T3 PL3307739T3 PL16810994T PL16810994T PL3307739T3 PL 3307739 T3 PL3307739 T3 PL 3307739T3 PL 16810994 T PL16810994 T PL 16810994T PL 16810994 T PL16810994 T PL 16810994T PL 3307739 T3 PL3307739 T3 PL 3307739T3
- Authority
- PL
- Poland
- Prior art keywords
- nrf2 regulators
- nrf2
- regulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175510P | 2015-06-15 | 2015-06-15 | |
EP16810994.0A EP3307739B1 (en) | 2015-06-15 | 2016-06-15 | Nrf2 regulators |
PCT/CN2016/085806 WO2016202253A1 (en) | 2015-06-15 | 2016-06-15 | Nrf2 regulators |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3307739T3 true PL3307739T3 (pl) | 2021-05-31 |
Family
ID=57545504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16810994T PL3307739T3 (pl) | 2015-06-15 | 2016-06-15 | Regulatory nrf2 |
Country Status (29)
Country | Link |
---|---|
US (3) | US10604509B2 (pl) |
EP (2) | EP3307739B1 (pl) |
JP (1) | JP6789995B2 (pl) |
KR (1) | KR20180018683A (pl) |
CN (1) | CN108112251B (pl) |
AU (1) | AU2016279388B2 (pl) |
BR (1) | BR112017027132A2 (pl) |
CA (1) | CA2988338A1 (pl) |
CL (1) | CL2017003226A1 (pl) |
CO (1) | CO2017012995A2 (pl) |
CY (1) | CY1123853T1 (pl) |
DK (2) | DK3307739T3 (pl) |
DO (1) | DOP2017000298A (pl) |
EA (1) | EA035864B1 (pl) |
ES (1) | ES2841574T3 (pl) |
HR (1) | HRP20202036T1 (pl) |
HU (1) | HUE052919T2 (pl) |
IL (1) | IL256297B (pl) |
LT (1) | LT3307739T (pl) |
MA (1) | MA52309A (pl) |
MX (1) | MX2017016405A (pl) |
PE (1) | PE20180799A1 (pl) |
PH (1) | PH12017502255A1 (pl) |
PL (1) | PL3307739T3 (pl) |
PT (1) | PT3307739T (pl) |
RS (1) | RS61302B1 (pl) |
SI (1) | SI3307739T1 (pl) |
WO (1) | WO2016202253A1 (pl) |
ZA (1) | ZA201708145B (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2988374A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
JP2018529745A (ja) | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーターとしてのビアリールピラゾール |
US10351530B2 (en) * | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
US11078216B2 (en) | 2016-12-14 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as NRF2 activators |
ES2848699T3 (es) * | 2016-12-14 | 2021-08-11 | Glaxosmithkline Ip Dev Ltd | Compuestos de 3-oxo-1,4-diazepinilo como activadores de NRF2 |
CN110114361B (zh) * | 2016-12-15 | 2022-04-12 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2化合物 |
US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
JP7064512B2 (ja) * | 2017-05-17 | 2022-05-10 | デナリ セラピューティクス インコーポレイテッド | キナーゼ阻害剤およびその使用 |
WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
EP3773536A4 (en) * | 2018-04-06 | 2022-01-05 | The Board of Trustees of the University of Illinois | 1,4-SUBSTITUTED ISOCHINOLINE INHIBITORS OF KEAP1 / NRF2-PROTEIN-PROTEIN INTERACTION |
UA126950C2 (uk) | 2018-08-20 | 2023-02-22 | Янссен Фармацевтика Нв | Інгібітори міжбілкової взаємодії keap1-nrf2 |
KR20210099622A (ko) | 2018-12-05 | 2021-08-12 | 가부시키가이샤 스코히아 파마 | 거대고리 화합물 및 그의 용도 |
CA3129955A1 (en) * | 2019-02-15 | 2020-08-20 | Glaxosmithkline Intellectual Property Development Limited | Hydroxypyridoxazepines as nrf2 activators |
CA3142295A1 (en) * | 2019-05-31 | 2020-12-03 | Ube Industries, Ltd. | Benzotriazole derivative |
US20230024995A1 (en) | 2019-07-03 | 2023-01-26 | Senju Pharmaceutical Co., Ltd. | Nrf2-activating compound |
CN110845435B (zh) * | 2019-11-28 | 2021-06-08 | 中国药科大学 | 一种过氧化氢响应型Keap1-Nrf2 PPI抑制剂前药、制备方法及其医药用途 |
KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
CN114539085B (zh) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | 一种脲基衍生物的制备 |
JPWO2022145459A1 (pl) | 2020-12-28 | 2022-07-07 | ||
TW202404984A (zh) * | 2022-04-28 | 2024-02-01 | 日商第一三共股份有限公司 | 苯并三唑化合物 |
TW202345792A (zh) * | 2022-04-28 | 2023-12-01 | 日商第一三共股份有限公司 | 苯并噻吩化合物 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
CA1224992A (en) | 1982-10-08 | 1987-08-04 | Robert E. Newell | Device for administering medicament to patients |
FI88112C (fi) | 1985-07-30 | 1993-04-13 | Glaxo Group Ltd | Anordning foer administrering av laekemedel till patienter |
SK280967B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Inhalačný prístroj |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
ES2107557T3 (es) | 1991-12-10 | 1997-12-01 | Shionogi & Co | Derivado de acido hidroxamico a base de sulfonamida aromatica. |
DE4220983A1 (de) * | 1992-06-26 | 1994-01-05 | Bayer Ag | Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate |
AU701776B2 (en) | 1994-05-27 | 1999-02-04 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
JP2004532187A (ja) | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 三置換カルボサイクリックサイクロフィリン結合化合物とその用途 |
WO2002080899A1 (fr) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Agent de traitement de maladie digestive |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
CA2726702A1 (en) | 2001-09-21 | 2003-04-03 | Bristol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
WO2004007464A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | イミダゾール誘導体 |
JP2006522130A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
EP1876179B1 (en) | 2005-04-28 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Thienopyrimidone compounds |
GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
ES2436028T3 (es) | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
WO2010005922A1 (en) | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US20140256767A1 (en) | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
JP6095580B2 (ja) * | 2012-02-13 | 2017-03-15 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
US20160046616A1 (en) * | 2013-03-15 | 2016-02-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
CA2934216C (en) * | 2013-12-18 | 2021-03-16 | Glaxosmithkline Intellectual Property Development Limited | Substitued phenyl or benzyl propanote derivatives and pharmaceutical compositiions thereof useful as nrf2 regulators |
CA2988374A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
RU2018101077A (ru) | 2015-06-15 | 2019-07-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Регуляторы nrf2 |
JP2018529745A (ja) | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーターとしてのビアリールピラゾール |
US10351530B2 (en) | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
-
2016
- 2016-06-15 PT PT168109940T patent/PT3307739T/pt unknown
- 2016-06-15 WO PCT/CN2016/085806 patent/WO2016202253A1/en active Application Filing
- 2016-06-15 BR BR112017027132A patent/BR112017027132A2/pt active Search and Examination
- 2016-06-15 EP EP16810994.0A patent/EP3307739B1/en active Active
- 2016-06-15 CA CA2988338A patent/CA2988338A1/en active Pending
- 2016-06-15 PE PE2017002744A patent/PE20180799A1/es unknown
- 2016-06-15 EA EA201890052A patent/EA035864B1/ru not_active IP Right Cessation
- 2016-06-15 PL PL16810994T patent/PL3307739T3/pl unknown
- 2016-06-15 US US15/736,075 patent/US10604509B2/en active Active
- 2016-06-15 HU HUE16810994A patent/HUE052919T2/hu unknown
- 2016-06-15 KR KR1020187000828A patent/KR20180018683A/ko active IP Right Grant
- 2016-06-15 SI SI201631036T patent/SI3307739T1/sl unknown
- 2016-06-15 CN CN201680048338.1A patent/CN108112251B/zh active Active
- 2016-06-15 ES ES16810994T patent/ES2841574T3/es active Active
- 2016-06-15 JP JP2017564886A patent/JP6789995B2/ja active Active
- 2016-06-15 MX MX2017016405A patent/MX2017016405A/es active IP Right Grant
- 2016-06-15 RS RS20210012A patent/RS61302B1/sr unknown
- 2016-06-15 MA MA052309A patent/MA52309A/fr unknown
- 2016-06-15 DK DK16810994.0T patent/DK3307739T3/da active
- 2016-06-15 LT LTEP16810994.0T patent/LT3307739T/lt unknown
- 2016-06-15 EP EP20200207.7A patent/EP3782996B1/en active Active
- 2016-06-15 DK DK20200207.7T patent/DK3782996T3/da active
- 2016-06-15 AU AU2016279388A patent/AU2016279388B2/en active Active
-
2017
- 2017-11-30 ZA ZA2017/08145A patent/ZA201708145B/en unknown
- 2017-12-11 PH PH12017502255A patent/PH12017502255A1/en unknown
- 2017-12-13 IL IL256297A patent/IL256297B/en active IP Right Grant
- 2017-12-15 DO DO2017000298A patent/DOP2017000298A/es unknown
- 2017-12-15 CL CL2017003226A patent/CL2017003226A1/es unknown
- 2017-12-19 CO CONC2017/0012995A patent/CO2017012995A2/es unknown
-
2019
- 2019-11-06 US US16/675,634 patent/US20200079759A1/en not_active Abandoned
-
2020
- 2020-12-21 HR HRP20202036TT patent/HRP20202036T1/hr unknown
- 2020-12-29 CY CY20201101223T patent/CY1123853T1/el unknown
-
2021
- 2021-10-06 US US17/495,115 patent/US20230047296A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL256297B (en) | Regulators of nrf2 | |
HK1256199A1 (zh) | Nrf2調節劑 | |
ZA201707785B (en) | Beamforming | |
DK3256579T3 (en) | Cysteinprotease | |
DK3256580T3 (en) | Cysteinprotease | |
DK3298030T3 (en) | Anti-cancerfusionspolypeptid | |
DK3250592T3 (en) | Anti-transthyretin-antistoffer | |
GB2555736B (en) | Fixing | |
DK3272750T3 (en) | Morphinan-derivat | |
AU361999S (en) | Ballustrade | |
GB201610183D0 (en) | Structure | |
GB201511225D0 (en) | Novel structure | |
PL3257657T3 (pl) | Struktura zapobiegająca wyciekaniu | |
DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
DK3282866T3 (en) | Proteinfibre | |
GB201610190D0 (en) | Structure | |
DK3294653T3 (en) | Justerbar inline-port | |
ZA201807587B (en) | Polytunnel structure | |
DK3242882T3 (en) | Cgrp-antagonistpeptider | |
GB201514625D0 (en) | Regulator | |
AU5516P (en) | LEP08 Lepidosperma squamatum | |
AU5511P (en) | PTK647 Epichloe coenophiala | |
GB201520684D0 (en) | Aeroplanes | |
AU366552S (en) | Nutblock | |
GB201515248D0 (en) | Polytunnel structure |